Mineralocorticoid receptor antagonists for the treatment of heart failure and kidney disease: a state-of-the-art review.

Re-analysis by subpopulation showed a nominally significant reduction in the primary outcome in the subpopulation of participants enrolled in the Americas, who had characteristics consistent with clinical HF and per-protocol study medication use (Table 1 ) [ 12 , 34 ].

also in 7,732 other papers